Indivior Pharmaceuticals, Inc. INDV Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.29B+4.1% | $1.24B+5.0% | $1.18B+0.6% | $1.17B+0.3% | $1.17B-1.5% | ||
| $242M-1.6% | $246M+8.4% | $227M+8.1% | $210M-11.4% | $237M+2.6% | ||
| $1.05B+5.5% | $994M+4.2% | $954M-1.0% | $964M+3.2% | $934M-2.5% | ||
| 81.3%+1.1pp | 80.2%-0.6pp | 80.8%-1.3pp | 82.1%+2.4pp | 79.8%-0.8pp | ||
| $91M-6.2% | $97M-9.3% | $107M+11.5% | $96M-5.0% | $101M-5.6% | ||
| $626M-1.4% | $635M+2.3% | $621M+2.1% | $608M+1.0% | $602M-1.6% | ||
| —— | —— | —— | —— | $905M-1.6% | ||
| $333M+27.1% | $262M+15.4% | $227M+3.7% | $219M+655% | $29M-23.7% | ||
| 25.8%+4.7pp | 21.1%+1.9pp | 19.2%+0.6pp | 18.7%+16.2pp | 2.5%-0.7pp | ||
| $40M-11.1% | $45M-13.5% | $52M+2.0% | $51M+13.3% | $45M+7.1% | ||
| $295M+23.4% | $239M+21.9% | $196M+3.7% | $189M+3,050% | $6M-70.0% | ||
| —— | —— | $67M-16.3% | $80M+515% | $13M0.0% | ||
| $251M+20.1% | $209M+63.3% | $128M+18.5% | $108M+1,643% | -$7M-200% | ||
| 19.4%+2.6pp | 16.9%+6.0pp | 10.8%+1.6pp | 9.2%+9.8pp | -0.6%-1.2pp | ||
| $1.95+18.9% | $1.64+62.4% | $1.01+20.2% | $0.84+4,300% | -$0.02-140% | ||
| $342M+25.7% | $272M+13.3% | $240M+3.0% | $233M+442% | $43M-20.4% | ||
| 26.5%+4.6pp | 21.9%+1.6pp | 20.3%+0.5pp | 19.8%+16.2pp | 3.7%-0.9pp | ||
| $333M+27.1% | $262M+15.4% | $227M+3.7% | $219M+655% | $29M-23.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Indivior Pharmaceuticals, Inc. 's profit margins?
- Gross margin is 81.3% and operating margin is 25.8%, with a 19.4% net margin.
- Where does Indivior Pharmaceuticals, Inc. 's income statement data come from?
- Every line is extracted from Indivior Pharmaceuticals, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.